WHAT IS CLAIMED IS:

- 1. A method for treating Hepatitis B virus (HBV)
 infection, comprising administering a compound that modulates
 the synthesis or expression of a target cellular gene or the activity of a target protein to a subject in need of such treatment.
 - 2. The method of Claim 1 in which the target gene is a Pyk2 kinase.
 - 3. The method of Claim 2 in which the compound is an antisense or ribozyme molecule that blocks translation of the Pyk2 kinase.
 - 4. The method of Claim 2 in which the compound is complementary to the 5 region of the target gene and blocks transcription via triple helix formation.
 - 5. The method of Claim 1 in which the target protein 20 is a Pyk2 kinase.
 - 6. The method of Claim 5 in which the compound inhibits the kinase activity of the Pyk2 kinase.
 - 7. The method of claim 6 in which the compound is a tyrphostin-derived inhibitor or a pharmaceutically acceptable salt thereof.
 - 8. The method of Claim 6 in which the compounds is a pyrozolopyrimidine, a derivative thereof or a pharmaceutically acceptable salt thereof.

20

- 9. The method of Claim 6 in which the compound is a derivative of benzylidenemalonitrile or a pharmaceutically acceptable salt thereof.
- 5 10. The method of Claim 5 in which the compound interferes with the interaction of Pyk2 kinase with other cellular or viral proteins.
- 11. The method of Claim 10 in which the compound is a dominant-negative mutant of Pyk2 kinase.
 - 12. The method of Claim 10 in which the compound is a phosphotyrosine containing peptide or a derivative thereof.
- 13. The method of Claim 1 in which the target protein 15 is HBx.
 - 14. A method for treating Hepatitis B virus infection, comprising administering a compound that modulates HBx activities required for viral replication.
 - 15. The method of Claim 17 in which the compound modulates the activation of a cytosolic calcium release.
- 16. The method of Claim 15 wherein the compound is Cyclosporin A.
 - 17. The method of Claim 15 in which the compound inhibits or interferes with the activity of a mitrochondrial calcium channel.
- 18. The method of Claim 15 in which the compound inhibits or interferes with the activity of Endosplasmic Reticulum calcium channel.

19. A pharmaceutical formulation for the treatment of HBV infection, comprising a compound that inhibits activation of a Pyk2 kinase, mixed with a pharmaceutically acceptable carrier.

5

20. A pharmaceutical formulation for the treatment of HBx infection, comprising a compound that inhibits HBx mediated activation of a Pyk2 kinase signaling cascade, mixed with a pharmaceutically acceptable carrier.

10

21. A pharmaceutical formulation for the treatment of HBV infection that inhibits the activities of the HBx gene product essential to sustain the HBV life cycle, mixed with a pharmaceutically acceptable carrier.

15

20

25

30